What changed
Recent developments highlight a divergence in the market's view of the two primary GLP-1 leaders. Novo Nordisk (NVO) has faced downward pressure as Citi cut its price target to DKK 296, citing concerns over limited margin growth. Furthermore, while Novo raised its outlook, it specifically targeted "average growth" rather than the high-growth trajectory previously expected by some investors. In contrast, Eli Lilly (LLY) showed significant momentum with a 44.7% revenue increase in 2025 and sustained shareholder returns despite recent price volatility. Additionally, new Phase 3b data on LLY's Taltz and Zepbound has provided deeper insights into the interconnected immune and metabolic biology of obesity, while other players like Foundayo have shown promising results compared to oral Semaglutide.
Why it matters
Eli Lilly’s strong revenue growth (44.7%) and the continued expansion of its pipeline (including Retatrutide) reinforce the "supercycle" thesis by proving that demand for these therapies is structurally high enough to overcome current valuation concerns. The discovery of linked immune and metabolic pathways further expands the addressable market, potentially extending the lifecycle of these drugs into new therapeutic areas beyond simple weight loss.
Conversely, Novo Nordisk’s shift toward "average growth" and the subsequent price target cut by Citi suggest that the market is beginning to price in a maturation phase for its specific portfolio. The move from high-growth expectations to "average" targets indicates that while the product demand remains, the ease of achieving outsized margins may be diminishing due to competition or manufacturing constraints. This creates a bifurcated outlook where Lilly is seen as the primary vehicle for continued expansion, while Novo’s path is increasingly viewed through the lens of margin sustainability and established market positioning.
Opposing sources and risks
Several reports suggest that the peak of the "supercycle" may already be reflected in current valuations. Citi's price target cut specifically highlights a risk to the thesis: if margins for GLP-1 drugs begin to compress due to competition or production costs, the rapid upward trajectory of the sector could flatten. Additionally, some analysts have labeled Novo Nordisk as a "value trap," suggesting that its lower valuation relative to Lilly might be a reflection of structural hurdles rather than an undervalued opportunity.
What to watch
- The results and strategic clarity presented at Novo's Capital Markets Day 2026.
- Clarification on the specific "uncomfortable details" within Eli Lilly's latest earnings filings.
- Regulatory developments regarding the safety and legality of compounded GLP-1 medications.
- Progress on the Denecimig BLA review following FDA facility remediation work.
- Clinical data updates for emerging peptide candidates like Retatrutide and Foundayo.
Related Arbora context
- concept-healthcare-managed-care-aging-demographics
- concept-pfizer-largecap-pharma-value-recovery
- concept-pharma-china-supply-chain-decoupling-pressure
- concept-mrna-platform-expansion-beyond-vaccines
- concept-healthcare-pharm_pipeline-catalysts
Sources
- https://investorshub.advfn.com/market-news/article/37777/citi-cuts-novo-nordisk-price-target-to-dkk-296-on-limited-margin-growth-outlook?
- https://finance.yahoo.com/healthcare/articles/novo_nordisk_nvo_raised_outlook_132822998.html?
- https://finance.yahoo.com/healthcare/articles/eli_lilly_lly_zepbound_retatrutide_151245229.html?
- https://finance.yahoo.com/healthcare/articles/nvos_semaglutide_push_create_growth_130200481.html?
- https://www.fool.com/coverage/better_buy/2026/10/06/eli_lilly_and_vs_novo_nordisk_as_which_healthcare_stock_is_a_better_buy_in_2026/
- https://finance.yahoo.com/healthcare/articles/foundayo_showed_better_results_oral_131551228.html?
This is research notes, not financial advice.